Locally Advanced, Metastatic Solid Tumors Clinical Trial
Official title:
A Phase I Dose Escalation Study of MK-2206 in Combination With Standard Doses of Selected Chemotherapies or Targeted Agents in Patients With Locally Advanced or Metastatic Solid Tumors
The purpose of this study is to compare the safety and tolerability of several dose levels of
MK-2206 in combination with chemotherapy and targeted therapy agents in participants with
locally advanced or metastatic solid tumors.
The primary hypotheses are that administration of MK-2206 in combination with either
carboplatin + paclitaxel, docetaxel, or erlotinib in participants with locally advanced or
metastatic solid tumors will have acceptable tolerability, a dose limiting toxicity (DLT)
rate of ≤30%, plasma exposure and pharmacodynamics that exceed target thresholds, and allow
for definition of a maximum tolerated dose (MTD) in each of the 3 combinations.
n/a